PPIPT00014

Target Protein Information
Protein_Name Erythropoietin receptor
Protein_Sequence MDKLRVPLWPRVGPLCLLLAGAAWAPSPSLPDPKFESKAALLASRGSEELLCFTQRLEDLVCFWEEAASSGMDFNYSFSYQLEGESRKSCSLHQAPTVRGSVRFWCSLPTADTSSFVPLELQVTEASGSPRYHRIIHINEVVLLDAPAGLLARRAEEGSHVVLRWLPPPGAPMTTHIRYEVDVSAGNRAGGTQRVEVLEGRTECVLSNLRGGTRYTFAVRARMAEPSFSGFWSAWSEPASLLTASDLDPLILTLSLILVLISLLLTVLALLSHRRTLQQKIWPGIPSPESEFEGLFTTHKGNFQLWLLQRDGCLWWSPGSSFPEDPPAHLEVLSEPRWAVTQAGDPGADDEGPLLEPVGSEHAQDTYLVLDKWLLPRTPCSENLSGPGGSVDPVTMDEASETSSCPSDLASKPRPEGTSPSSFEYTILDPSSQLLCPRALPPELPPTPPHLKYLYLVVSDSGISTDYSSGGSQGVHGDSSDGPYSHPYENSLVPDSEPLHPGYVACS
Organism_Source Mus musculus
Functional_Classification Class I cytokine receptor
Cellular_Localization Plasma membrane
Gene_Names Epor
UniProt_ID P14753
Protein-Protein Interaction Networks
Peptide Basic Information
Peptide_Name ML2-1
Peptide_Sequence RHVQKAESGLRSLTKLLREL
Peptide_Length 20
Peptide_SMILES CC(C)C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CCCNC(=N)N)C(C)C)[C@@H](C)O)C(=O)O
Chemical_Modification None
Cyclization_Method None
Linear/Cyclic Cyclic
N-terminal_Modification Free
C-terminal_Modification Free
Amino_Acid_Distribution
Peptide Physicochemical
Molecular_Weight 2334.75
Aliphatic_Index 117.00000
Aromaticity 0.00000
Average_Rotatable_Bonds 4.20000
Charge_at_pH_7 3.09184
Isoelectric_point 11.55036
Hydrogen_Bond_Acceptors 33
Hydrogen_Bond_Donors 39
Topological_Polar_Surface_Area 1061.02000
X_logP_energy -10.47859
Interaction Information
Affinity KD=14.3 uM
Affinity_Assay Surface Plasmon Resonance
PDB_ID None
Type Agonist
Structure
Reference Information
Document_Type Patent
Title USE OF ERYTHROPOIETIN - DERIVED PEPTIDE THROUGH EFFECT ON CELL DAMAGE PREVENTION THEREOF
Release_Year 2020
Patent_ID US20200407410A1